Publications & Presentations


June 2017 | ARQ 531 / Pre-clinical
ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in ABC-DLBCL and GCB-DLBCL
2017 European Hematology Association (EHA)
Presented by: S. Eathiraj, et al.

June 2017 | ARQ 092 / Pre-clinical
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines associated hypertrophic cardiomyopathy
PLOS One
Presented by: J. Wang, et al.

June 2017 | Tivantinib / HCC
Second-Line Tivantinib vs Placebo in Patients with MET-High Hepatocellular Carcinoma: Results of the METIV-HCC Phase 3 Trial
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Presented by: L. Rimassa, et al.

June 2017 | ARQ 092 / Pre-clinical
Results of a Phase 1b Study of ARQ 092 in Combination with Carboplatin (C) Plus Paclitaxel (P) or with Paclitaxel in Patients with Solid Tumors
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Presented by: N. Lakhani, et al.

June 2017 | ARQ 761 / Oncology
Phase 1 Study of ARQ 761, a ß-lapachone analog that promotes NQO1-mediated programmed cancer cell
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Presented by: D. Gerber, et al.

June 2017 | ARQ 092 / Pre-clinical
Efficacy of AKT inhibitor ARQ 092 compared with sorafenib in a cirrhotic rat model with hepatocellular carcinoma
Molecular Cancer Therapeutics
Presented by: G. Roth, et al.

June 2017 | ARQ 087 / iCCA
ARQ 087, an Oral Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients with Advanced Intrahepatic Cholangiocarcinoma (iCCA) with FGFR2 Genetic Aberrations
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Presented by: V. Mazzaferro, et al.

April 2017 | ARQ 092 / Pre-clinical
AKT inhibitor ARQ 092 and sorafenib additively inhibit progression of hepatocellular carcinoma
EASL – The International Liver Congress 2017
Presented by: Jilkova, et al.

March 2017 | ARQ 087 / Pre-clinicalARQ 092 / Pre-clinical
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Anticancer Drugs
Presented by: Y. Yu, et al.

February 2017 | ARQ 087 / Pre-clinical
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Translational Oncology
Presented by: R. Chila, et al.

December 2016 | ARQ 531 / Pre-clinical
The Bruton’s Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia
American Society of Hematology (ASH) Annual Meeting 2016
Presented by: S. Reiff, et al.

December 2016 | ARQ 092 / Pre-clinical
Specific inhibition of AKT with ARQ 092, an orally-available selective AKT inhibitor, attenuates acute vaso-occlusive events in sickle cell disease
American Society of Hematology (ASH) Annual Meeting 2016
Presented by: J. Li, et al.

November 2016 | ARQ 092 / Pre-clinical
In vivo Efficacy of the AKT Inhibitor ARQ 092 in Noonan Syndrome With Multiple Lentigines-Associated Hypertrophic Cardiomyopathy
American Heart Associate (AHA)
Presented by: J. Wang, et al.

November 2016 | ARQ 092 / Pre-clinical
Combination treatment by AKT inhibitor ARQ 092 and Sorafenib in a cirrhotic rat model with hepatocellular carcinoma
American Association for the Study of Liver Diseases (AASLD)
Presented by: Z. Jilkova, et al.

October 2016 | ARQ 092 / Pre-clinical
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
Haematologica
Presented by: K. Kim, et al.

October 2016 | Tivantinib / HCC
Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: an exploratory analysis from the ARQ 197-215 study
ESMO Congress 2016, Copenhagen, Denmark
Presented by: N. Personeni, et al.

September 2016 | ARQ 092 / Pre-clinical
Dual inhibition of AKT and KIT is synergistic in Gastrointestinal Stromal Tumor
Discovery on Target 2016, Boston, MA
Presented by: P. Zook, et al.

September 2016 | ARQ 087 / Pre-clinical
ARQ 087 inhibits fibroblast growth factor receptor (FGFR) signaling and rescues aberrant cell proliferation and differentiation in experimental models to craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3
EMBO Workshop - The modularity of signalling proteins and networks, Seefield in Tirol, Austria
Presented by: P. Krejci, et al.

September 2016 | ARQ 087 / Pre-clinical
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
PLOS ONE
Presented by: T. Hall et al.

September 2016 | ARQ 531 / Pre-clinical
Targeting Ibrutinib-Resistant BTK-C48S1 Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK
2016 Society of Hematologic Oncology Fourth Annual Meeting, Houston, TX
Presented by: S. Eathiraj, et al.

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300